Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / A toxoplasmose é uma zoonose amplamente distribuída que afeta mais de um terço da população mundial e de grande importância na saúde pública. A maioria das infecções em humanos por Toxoplasma gondii é assintomática. Entretanto, nos últimos anos, a toxoplasmose tem sido amplamente investigada uma vez que se apresenta como uma das doenças oportunistas que acometem pacientes portadores da Síndrome da Imunodeficiência Adquirida (AIDS) e indivíduos transplantados. A toxoplasmose congênita pode provocar aborto ou até sérios danos ao feto provocando retardo mental e cegueira em crianças, reduzindo significativamente a qualidade de vida dos sobreviventes. Assim, a transmissão congênita pode ser muito mais importante do que se pensava. Estudos sobre a evolução da infecção por Toxoplasma gondii em diferentes tipos de células hospedeiras se fazem necessários para uma abordagem terapêutica adequada. Nesse estudo utilizamos as técnicas de imunofluorescência e imunocitoquímica ultraestrutural com o objetivo de investigar a participação de Bax e Bcl-2, proteínas da família Bcl-2 que regulam a apoptose e a dinâmica mitocondrial durante a evolução da infecção das células endoteliais de veia umbilical humana (HUVEC) por taquizoítos de T. gondii. A microscopia confocal revelou uma rede mitocondrial filamentosa marcada pelo Mito Tracker Red no citoplasma de HUVEC e após 2h de infecção essa rede se mostrou desorganizada, provavelmente por conseqüência da invasão da HUVEC pelo T. gondii. Porém, em 6h de infecção, observamos a reestruturação da rede mitocondrial no citoplasma de HUVEC que se manteve no tempo de 20h de infecção. Ainda por microscopia confocal observamos que a proteína pró-apoptótica Bax se localiza principalmente no citoplasma, na mitocôndria, e pela primeira vez foi detectada no núcleo de HUVEC. No tempo de 2h de infecção, observamos a expressão de Bax principalmente na mitocôndria. Entretanto, após 6h e 20h de infecção, essa expressão diminuiu tanto na mitocôndria quanto no citoplasma de HUVEC. A expressão de Bcl-2 não foi observada em HUVEC não infectada e infectada por 2h, 6h e 20h. Taquizoítos de T. gondii apresentaram marcação positiva para Bax e Bcl-2 ao longo de todos os tempos de infecção. A análise ultraestrutural confirmou a dinâmica mitocondrial observada por microscopia confocal durante toda a interação. Os resultados de imunocitoquímica confirmaram a expressão de Bax no núcleo de HUVEC e a expressão de Bax e Bcl-2 em taquizoítos de T. gondii isolados. Portanto, nossos resultados sugerem que o T. gondii modula a morfologia da mitocôndria e a expressão de Bax em HUVEC, interferindo possivelmente nos mecanismos de defesa das células hospedeiras, entre eles a progressão da apoptose. / Toxoplasmosis is a zoonosis widely distributed that affects over a third of world population and is of great importance on public health. Most Toxoplasma gondii infection in humans is asymptomatic. However, on recent years toxoplasmosis has been investigated since it comes as some opportunistic diseases in patients with the acquired immunodeficiency syndrome (AIDS) and transplant patients. Congenital toxoplasmosis can cause miscarriage or serious damage to the fetus leading to mental retardation and blindness in children, significantly reducing the quality of life of survivors. Thus, congenital transmission can be much more important than previously thought. Studies on the development of Toxoplasma gondii in different host cells are necessary for an appropriate therapy. At this study we employed the immunofluorescence and ultrastructural immunocytochemical assay with the aim to investigate the involvement of Bax and Bcl-2, members of Bcl-2 family which regulate apoptosis and the mitochondrial dynamic during the infection progress of human umbilical vein endothelial cells (HUVEC) by tachyzoites of T. gondii. Confocal microscopy revealed a mitochondrial filamentous network stained by Mito Tracker Red within cytoplasm of HUVEC and after 2h of infection this network became desorganized, probably as a consequence of T. gondii invasion. However, at 6h of infection, we observed the restructuring of the mitochondrial network in the cytoplasm of HUVEC, which remained at the time of 20h of infection. Even by confocal microscopy we observed Bax pro-apoptotic protein located mainly in the cytoplasm, in the mitochondria, and for the first time it was detected in the nucleus of HUVEC. At the time of 2h of infection, we observed the expression of Bax mainly in mitochondria. However, after 6h and 20h of infection, this expression decreased such in mitochondria as in HUVEC cytoplasm. The Bcl-2 expression was not observed in uninfected and HUVEC infected for 2h, 6h and 20h. Tachyzoites of T. gondii presented positive labeling for Bax and Bcl-2 over all time of infection. The ultrastructural analysis confirmed the mitochondrial dynamics observed by confocal microscopy throughout the interaction. The results of immunocytochemistry confirmed Bax expression in the nucleus of HUVEC and the expression of Bax and Bcl-2 in isolated tachyzoites of T. gondii. Therefore, our results suggest that T. gondii modulates the mitochondria morphology and Bax expression in HUVEC, probably interfering on the host cells defense mechanisms, including the progression of apoptosis.

L'apoptose est un processus cellulaire fondamental pour l'homéostasie tissulaire. Ce type de mort cellulaire est sous le contrôle des protéines de la famille Bcl-2 qui régulent la perméabilité de la membrane externe de la mitochondrie. Cependant, au-delà de leur rôle dans le contrôle de l'apoptose, les protéines de la famille Bcl-2 peuvent intervenir dans d'autres processus tels que le cycle cellulaire ou le métabolisme. Au sein du laboratoire, nous nous intéressons tout particulièrement aux rôles non-apoptotiques des protéines Bcl-2 au cours du développement embryonnaire. Grâce à l'utilisation du poisson zèbre, nous avons pu montrer que les protéines de la famille Bcl-2 contrôlent différents processus au cours du développement grâce à leur capacité à réguler l'homéostasie calcique. En effet, nous avons montré que la protéine anti-apoptotique Nrz participe au remodelage du cytosquelette d'actine au cours de l'épibolie en régulant la concentration de calcium cytosolique par son interaction avec le récepteur à l'IP3 (IP3R). Nous avons de plus pu montrer que Nrz diminue la sortie de calcium du réticulum endoplasmique en inhibant la fixation de l'IP3 sur son récepteur. Nous avons également identifié un nouveau membre pro-apoptotique de la famille Bcl-2, Bclwav, spécifiquement exprimée chez les poissons et le xénope. Cette protéine participe à la régulation de l'homéostasie calcique mitochondriale en interagissant avec VDAC. Nous avons de plus montré que cette activité est essentielle pour les mouvements de convergence et d'extension au cours du développement embryonnaire précoce du poisson zèbre / Apoptosis is a key cellular process for tissue homeostasis. Apoptotic cell death is under control of Bcl-2 family proteins which regulate outer mitochondrial membrane permeability. However, beyond their role in apoptosis, Bcl-2 family proteins are also involved in other cellular processes such as cell cycle or metabolism. In our laboratory we are interested in non-apoptotic functions of Bcl-2 family proteins in embryonic development. Using zebrafish model we have shown that Bcl-2 proteins control different processes during early development thanks to their ability to regulate calcium homeostasis. Indeed, we have shown that the anti-apoptotic protein Nrz participates in actin cytoskeleton remodeling during epiboly by regulating cytosolic calcium concentration via an interaction with the IP3 receptor (IP3R). We have also demonstrated that Nrz decreases calcium release from the endoplasmic reticulum by inhibiting IP3 fixation on its receptor. We have furthermore identified a new pro-apoptotic member of Bcl-2 family, Bcl-wav which is expressed only in fish and frogs. This protein regulates mitochondrial calcium homeostasis by interacting with VDAC. We have moreover shown that this activity is essential for convergence and extension movements during early zebrafish development

Notre équipe étudie les mécanismes de résistance à l’apoptose induite par divers agents dans les cellules de lymphomes B infectées ou non par le virus d’Epstein-Barr (EBV). EBV est un virus oncogénique de la famille des gamma-herpès virus qui est associé notamment au lymphome de Burkitt (LB) et aux syndromes lymphoprolifératifs post-transplantation (PTLD). Des résultats précédents ont montré que l’utilisation de la nutline-3, une molécule capable de se fixer sur MDM2, active p53 dans ces cellules tumorales. Cependant cette activation de p53 provoque l’apoptose des cellules B EBV(-) alors que les cellules B EBV(+) en latence III (exprimant toutes les protéines virales dites « de latence ») sont beaucoup plus résistantes. Mon travail de thèse a consisté à étudier les mécanismes impliqués dans cette résistance afin de mettre en place des stratégies thérapeutiques pour la contourner. La première partie de ma thèse a été consacrée à l’étude du rôle de l’autophagie dans la résistance des cellules EBV(+) en latence III à l’apoptose. L’autophagie est un processus de dégradation des protéines qui joue un rôle physiologique complexe impliqué à la fois dans la survie et dans la mort cellulaire. Les travaux effectués ont montré que: 1) l’autophagie est induite en réponse au traitement par la nutline dans les cellules EBV(+) en latence III ; 2) ces cellules expriment fortement la Bécline-1 et présentent une activation constitutive de l’autophagie ; 3) l’autophagie participe à la résistance de ces cellules à l’apoptose. La seconde partie de ma thèse a été consacrée au développement de nouvelles molécules ciblant les protéines anti-apoptotiques de la famille de Bcl-2. En effet, outre Bcl-2 qui est surexprimé dans les cellules EBV(+), les cellules de LB et les PTLD surexpriment aussi Mcl-1, une autre protéine anti-apoptotique. Or il a été montré que cette protéine était fréquemment à l’origine de résistance à des inhibiteurs déjà développés (et en essais cliniques) contre Bcl-2. Le développement de molécules ciblant Mcl-1 s’avère donc utile pour les contrer. Pour cela une collaboration avec une équipe de chimiste (dirigée par Fanny Roussi à l’Institut de Chimie des Substances Naturelles à Gif-sur-Yvette) a été mise en place. Nous avons identifié et étudié les mécanismes d’action de plusieurs molécules inhibitrices potentielles de Mcl-1 et/ou Bcl-xL capables d’induire l’apoptose dans nos deux modèles de lymphomes. / Our team investigates the mechanisms of resistance to apoptosis induced in various B-cell lymphomas including some infected by the Epstein-Barr virus (EBV). EBV is an oncogenic member in the gamma-herpesvirus family. Among other pathologies, it is associated with Burkitt’s lymphoma (BL) and post-transplant lymphoproliferative disorders (PTLD). Previously, our laboratory has found that in these tumor cells, the binding of nutlin-3 to MDM2 results in the activation of p53. However, although p53 activation leads to apoptosis in EBV(-) cells, EBV(+) latency III cells which express all viral « latency » proteins are much more resistant. During this PhD project, I studied the mechanisms involved in this resistance and made attempts to define new therapeutic strategies that would bypass them. First, the role played by autophagy was investigated. This catabolic process which degrades proteins and organelles is physiologically complex as it is involved in both cell survival and cell death. Our work has demonstrated that: 1) autophagy was induced in nutlin-3 treated EBV(+) latency III cells; 2) Beclin-1 was strongly expressed in these cells whose autophagy was constitutively activated; 3) autophagy was involved in the resistance to apoptosis observed in these cells. Second, I turned my efforts to the identification of new molecules targeting anti-apoptotic members of the Bcl-2 family. Like Bcl-2, the antiapoptotic protein Mcl-1 is heavily expressed in LB and PTLD cell lines but in this case, independently of their EBV status and this is a frequent cause for the observed resistance to Bcl-2 inhibitors that are currently tested in clinical trials. Molecules targeting Mcl-1 could thus prove promising to circumvent this resistance. In a collaboration with a Chemistry team supervised by Fanny Roussi at the Institut de Chimie des Substances Naturelles in Gif-sur-Yvette, we have identified the mechanisms of action of potential inhibitors of Mcl-1 and/or Bcl-xL, another anti-apoptotic molecules which induce apoptosis in our two lymphoma models.

Les protéines BCL-2 jouent un rôle essentiel dans la décision de vie ou de mort des cellules. Elles contrôlent l'induction de l'apoptose (mort cellulaire programmée) par la voie mitochondriale via des fonctions opposées de régulateurs anti- et pro-apoptotiques. Les protéines contenant un ou plusieurs domaines dits d'homologie à Bcl-2 (BHl- 4) sont systématiquement classées dans cette famille. Grâce à une analyse bioinformatique et phylogénétique, nous avons revisité les différents critères d'inclusion dans le groupe de protéines BCL-2 et proposé une nouvelle classification tenant compte des données structurales et évolutives. Cette nouvelle nomenclature distingue : un premier groupe de protéines homologues (dérivant d'un ancêtre commun), partageant une structure 3D semblable à celle de Bcl-2 et pouvant ne posséder aucun motif BH, et un conglomérat, en pleine expansion, regroupant des protéines sans lien phylogénétique apparent et partageant une courte région de similarité de séquence correspondant au motif BH3. Sur la base de ces résultats, nous avons construit un processus, basé sur des profils HMM, pour identifier les protéines appartenant au groupe de protéines BCL-2. Notre processus automatisé est utilisé pour i) récupérer les séquences nucléotidiques et protéiques mensuellement ii) les annoter et iii) les intégrer dans la base de connaissances BCL2DB (« The BCL-2 Database »). Celle-ci est accessible via une interface Web (http://bcl2db.ibcp.fr) qui permet aux chercheurs d'extraire des données et d'effectuer des analyses de séquence / BCL-2 proteins play an essential role in the decision of life or death of animal cells. They control the induction of apoptosis (programmed cell death) in the mitochondrial pathway via regulators having opposite functions: anti- or pro-apoptotic. Proteins containing one or more Bcl-2 homology domains (BHl-4) are systematically classified in this family. Through bioinformatics and phylogenetic analysis, we revisited the different criteria for protein inclusion in the BCL-2 group and proposed a new classification taking into account structural and evolutionary data. This new nomenclature distinguishes a first group of homologous proteins (derived from a common ancestor), sharing a similar 3D structural fold with Bcl-2 and often (but not necessarily) having one or more BH motifs, and a fast expanding conglomerate of proteins without apparent phylogenetic relationships and sharing only a short region of sequence similarity corresponding to the BH3 motif. Based on these results, we built a process based on profiles HMM to identify proteins belonging to the BCL-2 protein group. Our automated process i) recovers on a monthly basis the nucleotide and protein sequences ii) annotates them and iii) integrates this information into BCL2DB ("The BCL-2 Database"). This resource can be accessed via a web interface (http://bcl2db.ibcp.fr) which allows researchers to extract data and perform sequence analysis

La mitochondrie joue un rôle capital dans la mort cellulaire programmée ou apoptose par l’intermédiaire des protéines de la famille Bcl-2. Le dérèglement de l'apoptose dans de nombreux cancers fait de cette voie et des protéines de la famille Bcl-2 des cibles prometteuses pour la thérapie anti-cancéreuse. Le développement de petites molécules ciblant les protéines de la famille Bcl-2 s’est toutefois révélé être un grand défi, et peu d’entre elles ont atteint des études de phase clinique. Cependant, depuis une quinzaine d’années, grâce à des approches variées et souvent innovantes, des composés très actifs ont été développés. Plusieurs composés sont actuellement en essais clinique et une molécule, le venetoclax, a obtenu la première autorisation de mise sur le marché en avril 2016. Ce succès thérapeutique démontre que les protéines de la famille de Bcl-2 sont des cibles potentielles pour la thérapie anticancéreuse.Les substances naturelles sont une source importante de nouvelles molécules à structures originales, et de nombreux médicaments utilisés actuellement en chimiothérapie sont d’origine naturelle. La meiogynine A est un triterpène dimère qui a été isolé et synthétisé dans notre équipe. Ce composé possède une activité inhibitrice duale des protéines anti-apoptotiques Bcl-xL et Mcl-1. Des analogues de première et deuxième génération ont été élaborés par la suite, parmi lesquels, certains présentent une activité duale sub-micromolaire. Contrairement aux analogues de première génération, ces composés ne sont cependant pas cytotoxiques, probablement en raison de la présence d’une fonction ester sur la chaine latérale qui peut s’hydrolyser en un métabolite inactif.Mon projet de thèse vise à élaborer des analogues de troisième génération de la meiogynine A possédant une activité inhibitrice multiple sub-micromolaire des protéines anti-apoptotiques Bcl-xL, Mcl-1, Bcl-2 et cytotoxiques sur des lignées cellulaires surexprimant ces mêmes protéines. Pour cela, un essai biologique de mesure d’inhibition de l’interaction Bcl-2/Bim a été mis en place et robotisé afin d’évaluer l’activité biologique des composés synthétisés. De plus, la voie de synthèse bioinspirée d’un précurseur commun des nouveaux analogues a été mise au point à l’échelle de plusieurs grammes. Ce précurseur a permis d’élaborer différents analogues de troisième génération de la meiogynine A en réalisant des pharmacomodulations sur la chaîne latérale afin de remplacer la fonction ester des analogues de deuxième génération par un groupement stable et résistant in cellulo. Différentes séries ont été envisagées (alcènes, amines, amides, carbamates et triazoles). L’activité biologique des composés synthétisés a été évaluée sur les trois cibles in vitro. Finalement, des analyses de cytotoxicité pour les analogues les plus actifs ont été réalisées par nos collaborateurs à l’Institut Gustave Roussy. / Apoptosis is used by multicellular organisms to regulate tissue homeostasis through the elimination of useless or potentially harmful cells. The key players of apoptosis are caspases, a family of proteases whose activation is induced by two major signalling pathways. One of these pathways (the intrinsic pathway) is regulated by the Bcl-2 family of proteins. In recent years, numerous studies have shown that overexpression of the antiapoptotic Bcl-2, Bcl-xL or Mcl-1 proteins is involved in the development of many kinds of cancers or confers resistance to apoptosis induced by standard anticancer therapies. Consequently, targeting this family of proteins is a highly promising strategy for tumour treatment.The feasibility of disrupting protein-protein interactions between anti- and pro-apoptotic members of the Bcl-2 family, using small-molecule inhibitors has been successfully established, and venetoclax was the first to obtain the FDA authorisation in April 2016 as an inhibitor of anti-apoptotic proteins of Bcl-2.Natural products are still playing a significant role in drug discovery and development process. Thus, from the 1940’s to date, 75% of the 175 small molecules used in cancer therapy, are either natural products or derivatives of natural compounds. Screening of plant extracts, marine organisms or microorganisms can provide highly original and functionalized bioactive molecules that are unlikely obtained by screening synthetic libraries. In fact, structural complexity is often a criterion of specificity for biological target.Meiogynin A is an original molecule isolated from a Malaysian Annonaceae and synthesized in our team in 2009. It exhibited a promising inhibitory activity of Bcl-2, Bcl-xL and Mcl-1, three anti-apoptotic proteins of Bcl-2 family whose overexpression is correlated with many cancers. 1st- and 2nd-generation analogs were further elaborated. Despite their remarkable affinity towards target proteins, 2nd-generation analogs lacked cytotoxicity, probably due to the presence of an ester linker that could undergo competitive hydrolysis in cellulo, leading to an inactive metabolite.We aim to develop 3rd-generation analogues of meiogynine A exhibiting high affinity towards multiple anti-apoptotic members of Bcl-2 family as well as cytotoxicity on cancer cells that overexpress these proteins. For this, a new fluorescence polarization inhibition test for Bcl-2/Bim interaction has been implemented, and meiogynine A and its analogues have been tested against the new interaction. In addition to Bcl-xL/Bak and Mcl-1/Bid interaction inhibition, these molecules showed an ability to inhibit Bcl-2/Bim interaction. Thus, they are considered multiple inhibitors.3rd-generation analogues of meiogynine A were obtained by pharmacomodulation of a common precursor that was synthesized on a gram-scale through a bioinspired Diels-Alder reaction. Several functional groups that have better stability in vivo than the ester group were anticipated, such as the amines, amides, carbamates and triazoles. Biological activity of the synthesized analogues was evaluated, and those presenting the best inhibitory profile were evaluated in cellulo by our collaborators in the Institut Gustave Roussy.

La protéine Bcl xL, membre de la famille de Bcl 2, est essentiellement décrite pour son rôle dans l'inhibition de la mort des cellules. Récemment, un nouveau rôle lui a été attribué dans la régulation de la macro-autophagie, processus principalement décrit pour promouvoir la survie des cellules. Bcl xL exerce donc ses fonctions de survie à travers la régulation d'au moins deux processus différents.Si les fonctions anti-apoptotiques de Bcl xL ne sont plus à démontrer, ses fonctions dans la régulation de l'autophagie sont davantage débattues. Ainsi, nous avons centré ce travail sur la caractérisation des fonctions pro-autophagiques de Bcl xL afin de mieux comprendre ses fonctions de survie. Nos résultats suggèrent que Bcl xL subit in vivo et dans des cellules en culture une modification de type déamidation. Nous montrons que cette modification renforce les fonctions pro-autophagiques de Bcl xL sans affecter ses fonctions anti-apoptotiques. Par ailleurs, nous nous sommes intéressés à l'interaction entre Bcl xL et la petite GTPase Rab7, une protéine essentielle au processus autophagique et endocytique. Nous avons généré, et analysé d'un point de vue fonctionnel, des mutants de Bcl xL de type perte ou gain d'interaction avec Rab7. Notre principale conclusion est que Bcl xL stimule le trafic des vésicules médié par Rab7, et nous proposons que les fonctions pro-autophagiques de Bcl xL sont majoritairement dépendantes de son interaction avec Rab7. Cette étude contribue ainsi à mieux définir les fonctions pro-autophagiques de Bcl xL ainsi que les processus qui les régulent. Par ailleurs, elle approfondit nos connaissances des fonctions oncogéniques de Bcl xL en intégrant la composante supplémentaire de ses fonctions pro-autophagiques, et ouvre ainsi des perspectives pour l'élaboration de nouvelles stratégies thérapeutiques anti-cancéreuses notamment. / Bcl xL, a member of the Bcl-2 family, is mainly described for its role in the inhibition of cell death. Recently, Bcl xL was attributed a new role in the regulation of macro-autophagy, a process described mainly for its contribution to cell survival. Hence, Bcl xL wields its survival functions through the regulation of at least two different processes. If the anti-apoptotic functions of Bcl xL are now well established, its role in the regulation of autophagy is more debated. Therefore we focused this work on the characterization of Bcl xL pro-autophagic functions in order to get a better understanding of its survival functions. Our results suggest that Bcl xL undergoes in vivo and in cultured cells a modification called deamidation. We show that this modification enhances its pro-autophagic functions without affecting its anti-apoptotic functions. In addition, we characterized an interaction between Bcl xL and the small GTPase Rab7 which is essential for autophagy and endocytosis. We generated mutants of Bcl xL either gaining or loosing interaction with Rab7. The functional analysis of these mutants suggested that Bcl xL stimulates the vesicle trafficking mediated by Rab7, and prompts us to hypothesize that Bcl xL pro-autophagic functions are mainly dependent on its interaction with Rab7. This study helps to better define the pro-autophagic functions of Bcl xL and the processes regulating them. It provides further insights in the oncogenic functions of Bcl xL by implementing additional component of its pro-autophagic functions, and opens perspectives for the development of new therapeutic strategies against cancer progression.

As estatísticas relacionadas aos cânceres hematológicos indicam que a incidência e mortalidade dessas doenças têm aumentado ao longo dos anos. Embora a maioria dos casos de linfomas e leucemias não possua etiologia definida, sugere-se que fatores genéticos possam estar envolvidos. Nesse contexto, destaca-se a família de proteínas Bcl-2, divididas em anti e pró-apoptóticas. Os genes Bcl-2 e Bcl-XL, membros de uma nova classe de oncogenes, que atuam no mecanismo de morte celular das células cancerígenas, sobretudo apoptose, a qual é controlada por numerosos sinais intra e extracelulares. Uma nova estratégia para o tratamento desta doença inclui a terapia gênica mediada por RNA de interferência, que silencia importantes genes, a exemplo dos genes da família Bcl-2. Visto que o silenciamento isolado de um único gene pode não ter resultados expressivos, o presente trabalho teve por objetivo desenhar um RNA de interferência (RNAi) homólogo a dois tipos distintos de RNA mensageiro (RNAm) e inibir simultaneamente os genes Bcl-2 e Bcl-XL,assim como testar a inibição isolada dos mesmos. Amostras de linhagem tumoral Jurkat e Granta-519 foram avaliadas após transfecção com os seguintes RNA:i Bcl-2,Bcl-XL, Bcl-2/Bcl-XL,Bcl-2+Bcl-XL e scramble. Os nossos achados evidenciam que, na linhagem Granta-519, a sequência do RNAi Bcl-2 inibe, isoladamente ou conjugado ao Bcl-XL, o gene Bcl-2. Deste modo, o RNAi Bcl-2 apresenta-se mais eficiente no mecanismo de silenciamento gênico, uma vez que propicia a morte celular frente a toxicidade do quimioterápico etoposide. / The hematological cancer statistics indicates that its incidence and mortality have increased over the years. Although most cases of lymphomas and leukemias has no definite etiology however is suggested that genetic factors may be involved. In this context there is the Bcl-2 proteins family divided into anti-apoptotic and pro-apoptotic which Bcl-2 and Bcl-XL genes are members of a new class of oncogenes that act in cancer cells death mechanisms, especially apoptosis, that is controlled by numerous intra-and extracellular signals. Among new strategies to treat hematological cancer includes gene therapy mediated by RNA interference, which can decrease expression of genes like Bcl-2 family components. Studies of single gene silencing have not shown significant results so this study aimed to design an RNA interference (iRNA) homologous to two distinct types of messenger RNA (mRNA) and inhibit both genes Bcl-2 and Bcl-XL -XL as well as test the inhibition. Commercial cells Jurkat and Granta-519 were evaluated after transfection with iRNA as follows: Bcl-2, Bcl-XL, Bcl-2/Bcl-XL, Bcl-2+Bcl-XL and scramble. Our findings show that in Granta-519 cell line Bcl-2 RNAi sequence inhibits, alone or conjugated to Bcl-XL, Bcl-2 gene. Thus RNAi Bcl-2 appears more effective in gene silencing mechanism as it promotes cell death due chemotherapeutic agent etoposide toxicity.

Para que ocorra a transição do epitélio normal de laringe para carcinoma escamoso é necessário um processo de múltiplas etapas tal como exposição prolongada ao fumo e álcool e uma possível associação à infecção pelo HPV. Vários tipos de marcadores moleculares vêm sendo estudados na carcinogênese da laringe, entre eles proteínas associadas a apoptose (bcl-2 e PARP-1) assim como proteínas envolvidas em múltiplos processos biológicos como a Galectina-3. Neste estudo foram realizadas análise imunoistoquímica quantitativa e qualitativa para bcl-2, PARP-1 e galectina-3 em 65 pacientes diagnosticados com câncer de laringe subdivididos em: carcinoma de laringe in situ (CLIS), carcinoma de laringe com metástase (CLM), sem metástase (CLS) e linfonodos cervicais (LC). A detecção e tipificação do HPV foram realizadas pela reação em cadeia da polimerase (PCR) e os tipos de HPV avaliados foram HPV 6, 11, 16, 18, 31 e 33. Na avaliação quantitativa de galectina-3 observou-se um significativo aumento de expressão no carcinoma invasivo de laringe (CLS e CLM) quando comparado com carcinoma in situ (CLIS), podendo concluir que essa proteína seria um bom marcador pra progressão de câncer de laringe. Para as proteínas PARP-1 e bcl-2 não houve diferença nos níveis de expressão nos grupos analisados. Na análise qualitativa PARP-1 apresentou uma homogeneidade de marcação tanto alta como baixa entre os grupos. Em relação à Galectina-3 observou-se um predomínio de casos com alta expressão, diferentemente da proteína bcl-2 onde o predomínio foi de baixa expressão em todos os casos de carcinoma de laringe e seus respectivos linfonodos metastáticos. Dos 65 pacientes, 55 (84,6%), foram positivos para beta-globina e 7 (12.7%) dos 55 pacientes foram positivos para HPV. Não foi possível verificar quaisquer correlações entre as proteínas Galectina-3, bcl-2 e PARP-1 e o HPV devido ao baixo índice de casos positivos. / To occur the transition from normal epithelium to squamous cell carcinoma is a necessary a for multiple stages process, such as smoking and alcohol abuse and a possible association with HPV infection. Several types of molecular markers have been studied in cancer of larynx, including proteins associated with apoptosis (bcl-2 and PARP-1) and proteins involved in many biological process such as galectin-3. In this study, analyses of qualitative and quantitative immunohistochemistry was performed for bcl-2, PARP-1 and galectin-3 in 65 patients diagnosed with laryngeal squamous cell carcinoma divided into in situ laryngeal carcinomas(LSCCS), laryngeal squamols cells carcinomas without metastases (LSCCWT) and with metastasis (LSCCW) and cervical lymph nodes (CL). HPV detection and typing was performed by PCR and the HPV types evaluated were HPV 6, 11, 16, 18, 31 and 33. In quantitative of galectin-3 there was observed a significant increase of expression in invasive laryngeal squamous cell carcinoma (LSCCWT and LSCCW) compared with in situ laryngeal carcinomas (LSCCS), may indicating that this protein could be a good marker for progression of laryngeal carcinoma. For PARP-1 and bcl-2 protein there was no difference in the levels of expression in all groups studied. In qualitative analysis PARP-1 showed a homogenous immunolabeling in both high and low among the groups. In relation to Galectin-3, it was observed a predominance of cases with high expression, unlike the protein bcl-2 where the expression prevalence was low in all cases of laryngeal carcinoma and their metastatic lymph nodes. Of the 65 patients, 55 (84.6%) were positive for beta-globin and 7 (12.7%) of 55 patients were positive for HPV. Because of a low incidence of HPV in the cases studied, it was not possible correlate the proteins bcl-2, PARP-1 and Galectin-3 with the presence of HPV.

Das Neuroblastom, ein embryonaler Tumor des sympathischen Nervensystems, stellt durch seine außerordentliche Heterogenität klinisch eine große Herausforderung dar. Ziel dieser Arbeit war es, die Expression der GATA-Transkriptionsfaktoren GATA-2, -3, -4 und des Kofaktors friend-of-GATA (FOG)-2 im Neuroblastom und im sich entwickelnden sympathischen Nervensystem zu vergleichen. Davon ausgehend wurde die Rolle der Proteine im Neuroblastom näher untersucht. Es wurde gezeigt, dass alle vier Proteine in humanem Neuroblastom-Gewebe sowie in einer humanen Neuroblastom-Zelllinie (SH-SY5Y) exprimiert werden und nukleär lokalisiert sind. Lediglich Gata-4 wurde jedoch im sich entwickelnden sympathischen Nervensystem der Maus nicht exprimiert. Die Einzigartigkeit von GATA-4 bestätigte sich auch durch Microarray-Analysen von 251 Neuroblastom-Proben. Während GATA-2, -3 und FOG-2 signifikant mit Markern für eine günstige Prognose assoziiert wurden, korrelierte die GATA-4 Expression mit MYCN-Amplifikation. Interessanterweise führte die lentivirale Überexpression von GATA-4 zu einer Proliferationsinhibition humaner Neuroblastomzellen (SH-SY5Y und SH-EP) sowie zu der verstärkten Expression von DPYSL3 und Bcl-2. Zudem konnte durch das Differenzierungsagens Retinsäure die GATA-4 Expression induziert werden. So wurde in dieser Arbeit bestätigt, dass normale Entwicklungsprozesse in prognostisch günstigen Neuroblastomen intakt sind. Umgekehrt sind in Tumoren mit schlechterer Prognose diese Prozesse gestört. Die in vitro verlangsamte Proliferation sowie die Induktion von Bcl-2 nach Überexpression von GATA-4 könnten in vivo bei der schlechteren Therapierbarkeit der prognostisch ungünstigen Neuroblastome eine Rolle spielen. Es ist bekannt, dass die Behandlung mit Retinsäure u. a. durch Bcl-2 zu einer Chemoresistenz führen kann. Da die Expression von GATA-4 durch Retinsäure induziert werden und GATA-4 die Expression von Bcl-2 verstärken kann, könnte GATA-4 an der Chemoresistenz beteiligt sein. / Neuroblastoma, an embryonal tumor of the sympathetic nervous system, remains clinically challenging due to its extreme heterogeneity. The aim of this study was to compare the expression of GATA transcription factors GATA-2, -3, -4 and the cofactor friend-of-GATA (FOG)-2 in neuroblastoma and in the developing sympathetic nervous system. The functional role of these proteins in neuroblastoma was subsequently investigated based on the results of the GATA expression studies. The analysis showed that all four proteins are expressed in human neuroblastoma tissue as well as in a human neuroblastoma cell line (SH-SY5Y) and are localized in the cell nuclei. Only Gata-4, however, was not expressed in the developing murine sympathetic nervous system. Its uniqueness was also confirmed by microarray analyses of 251 neuroblastoma specimens. While GATA-2, -3 and FOG-2 were significantly associated with favorable prognostic markers, GATA-4 expression correlated with MYCN-amplification. Interestingly, lentiviral GATA-4 overexpression led to inhibited proliferation of human neuroblastoma cells (SH-SY5Y and SH-EP) as well as to increased expression of DPYSL3 and Bcl-2. In addition, GATA-4 expression could be induced by the differentiation agent retinoic acid. In conclusion, it was confirmed that normal developmental molecular pathways are intact in prognostically favorable neuroblastoma. In contrast, these developmental processes seem to be defective in tumors with unfavorable prognosis. The slowed proliferation, as observed in vitro, as well as the induction of Bcl-2 brought about by GATA-4 overexpression may contribute in vivo to the difficult treatability of prognostically unfavorable neuroblastoma. It is known that treatment of neuroblastoma with retinoic acid can lead to chemoresistance, mediated by Bcl-2 amongst others. Since retinoic acid can induce the expression of GATA-4 and GATA-4 itself can enhance the expression of Bcl-2, GATA-4 could be involved in chemoresistance.

Le laboratoire a récemment identifié la protéine Damaged-DNA-Binding 2 (DDB2), connue à l’origine pour son rôle dans la réparation de l’ADN comme une protéine impliquée dans la tumorigenèse mammaire. En effet, nous avons montré son rôle dans la croissance et la progression des tumeurs mammaires via la régulation transcriptionnelle de gènes cibles. Dans ce travail, nous avons montré que la surexpression de DDB2 augmente la sensibilité des cellules tumorales MDA-MB231 et SKBr3 traitées à la doxorubicine et au 5-fluorouracile (5-FU). Inversement, l’inhibition de l’expression de DDB2 dans les cellules T47D qui l’expriment naturellement s’accompagne d’une baisse de la sensibilité à ces agents anticancéreux. Nos résultats montrent que la sensibilité des cellules au 5-FU mais pas à la doxorubicine, lorsque DDB2 est surexprimée, dépend en partie du contrôle négatif qu’exerce cette dernière sur l’activité de NF-κB, en régulant positivement l’expression d’IκBα. Enfin, la recherche d’autres gènes cibles de DDB2, impliqués dans l’apoptose, nous a conduits à celui codant le facteur anti-apoptotique Bcl-2. DDB2 agit négativement sur l’expression de Bcl-2 en interagissant avec une région de l’ADN localisée dans le promoteur P2 du gène correspondant. De part, son rôle anti-apoptotique, la régulation de son expression pourrait bien être à l’origine de la sensibilité aux agents anticancéreux induite par DDB2. L’ensemble de ces résultats met donc en évidence l’intérêt clinique de DDB2 comme marqueur prédictif de la réponse aux agents anticancéreux, et devrait contribuer à une meilleure compréhension des mécanismes impliqués dans l’échappement des cellules tumorales aux thérapies / The laboratory has recently identified the Damaged-DNA Binding 2 protein (DDB2), a protein involved in DNA repair, as an important actor in breast tumorigenesis. Our laboratory has shown that DDB2 is involved in breast tumor growth and progression through the transcriptional regulation of target genes. Thus, the first aim of this work was to study the role of DDB2 and its target genes in the response of breast cancer cells to anticancer drugs. We showed that DDB2 overexpressed in breast cancer cell lines, such as MDA-MB231 and SKBr3, increased the cells sensitivity to apoptosis induced by doxorubicin and 5-Fluorouracil (5-FU). Conversely, the inhibition of DDB2 expression in T47D cells, which express endogenously this protein, decreased cell sensitivity to anticancer agents. Our results showed that cell sensitivity induced by DDB2 expression to 5-FU but not doxorubicin depended on its ability to repress NF-κB activity via the regulation of IκBα expression. At last, the search of potential DDB2 target genes implicated in apoptosis has led us to identify the anti-apoptotic factor Bcl-2. We showed the ability of DDB2 to downregulate Bcl-2 expression via its interaction with DNA region located in P2 promoter of the corresponding gene. Results suggest that Bcl-2 dowregulation by DDB2 could be a major event that explains the enhanced sensitivity of cancer cells to therapeutic agents. Altogether, these data highlight the clinical interest of DDB2, as a predictive marker of the response to anticancer agents. A better understanding of its mode of action will contribute to improve therapeutic treatments and avoid their failure in resistant patients